Pulse Biosciences (PLSE)
Develops nPulse systems for soft-tissue and atrial-fibrillation ablation.
Deutsche Bank AG Takes Position in Pulse Biosciences, Inc $PLSE
Deutsche Bank AG purchased a new stake in Pulse Biosciences, Inc (NASDAQ: PLSE) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 24,786 shares of the company's stock, valued at approximately $687,000. Several other institutional investors and hedge funds have also added to
Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE
Bank of America Corp DE raised its holdings in shares of Pulse Biosciences, Inc (NASDAQ: PLSE) by 8.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 866,061 shares of the company's stock after buying an additional 65,884 shares
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High – Here’s Why
Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The stock traded as high as $48.10 and last traded at $46.00, with a volume of 525728 shares trading hands. The stock had previously closed at $46.79. Analyst Upgrades and Downgrades PLSE has been the subject
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Conference.
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment.
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approxim.
Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Pulse Biosciences' Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presenta.
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in listening to the c.
Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock warrants issued by the Company as part of its July 3, 2024 rights offering. These outstanding common stock warrants (the “200% Warrants”), which were issued in the Com.
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy amid recent stock price gains.
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences' common stock through its at-the-market equity offering program (ATM) during the Company's designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Bi.
Pulse Biosciences Q1 Earnings Call Highlights
Pulse Biosciences NASDAQ: PLSE said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program.
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, NV. Pulse Biosciences' Management is scheduled to present on Wednesday, May 13, at 4:35 pm PT. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the.
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.